Literature DB >> 206298

Role of microtubules in granulocyte adherence.

L A Boxer, J M Allen, A M Watanabe, H R Besch, R L Baehner.   

Abstract

The adherence of human polymorphonuclear leukocytes (PMN) to nylon fibers is inhibited in a dose-dependent fashion by exposure in vitro of these cells to either colchicine or VM-26, both of which agents prevent microtubule assembly. Mean adherence of human PMN was 48% +/- 2%, following treatment with 10(-5) M colchicine or 10(-4) M VM-26 it was reduced to 31% +/- 2% and 7%, respectively. Peritoneal PMN obtained from mice and mink with Chediak-Higashi syndrome (CHS) thought to have a microtubule-membrane disorder affecting the PMN had a mean adherence of 29% +/- 3% and 40% +/- 8% compared to control values of 46% +/- 5% and 73% +/- 8%, respectively, from the mice and mink. Both ascorbic acid and bethanechol, shown previously to enhance microtubule assembly in humans with CHS, normalized granulocyte adherence in PMN obtained from mice with CHS. Cyclic nucleotide levels were not altered by treatment of human PMN with colchicine, nor did they differ between normal and CHS animals. Thus it appears that the state of microtubule assembly may directly affect the properties of the PMN plasma membrane without requiring alterations of cyclic nucleotides as an intermediary.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 206298

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Digital integration of granulocyte aggregation responses. A simple and reproducible method for the quantitation of granulocyte adhesiveness.

Authors:  P R Craddock; J G White; D J Weisdorf; D E Hammerschmidt
Journal:  Inflammation       Date:  1980-12       Impact factor: 4.092

2.  The phagocytosis of yeast cells by blood monocytes. Effects of therapeutic concentrations of Vinca alkaloids.

Authors:  L Athlin; L Domellöf; B Norberg
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Diminished polymorphonuclear leukocyte adherence. Function dependent on release of cyclic AMP by endothelial cells after stimulation of beta-receptors by epinephrine.

Authors:  L A Boxer; J M Allen; R L Baehner
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

4.  A thiol proteinase inhibitor, E-64-d, corrects the abnormalities in concanavalin A cap formation and the lysosomal enzyme activity in leucocytes from patients with Chediak-Higashi syndrome by reversing the down-regulated protein kinase C activity.

Authors:  S H Cui; F Tanabe; H Terunuma; Y Iwatani; H Nunoi; K Agematsu; A Komiyama; A Nomura; T Hara; T Onodera; T Iwata; M Ito
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

5.  Comparative studies on the adhesiveness of granulocytes of guinea pig and man.

Authors:  D Ehlers; I Sakowski; W Mohrig
Journal:  J Comp Physiol B       Date:  1989       Impact factor: 2.200

6.  Membrane fluidity in human and mouse Chediak-Higashi leukocytes.

Authors:  R A Haak; L M Ingraham; R L Baehner; L A Boxer
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

7.  Enhancement of human polymorphonuclear leukocyte adherence to plastic and endothelium by phorbol myristate acetate. Comparison with human C5a.

Authors:  R O Webster; R B Wysolmerski; D Lagunoff
Journal:  Am J Pathol       Date:  1986-11       Impact factor: 4.307

8.  Concanavalin A capping in polymorphonuclear leukocytes.

Authors:  M Rister; G Brucke; F Wegener; E Gladtke
Journal:  Eur J Pediatr       Date:  1980-12       Impact factor: 3.183

9.  Abnormal mobility of neonatal polymorphonuclear leukocytes. Relationship to impaired redistribution of surface adhesion sites by chemotactic factor or colchicine.

Authors:  D C Anderson; B J Hughes; C W Smith
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

10.  The Chediak-Higashi gene in humans. III. Studies on the mechanisms of NK impairment.

Authors:  J C Roder; R F Todd; P Rubin; T Haliotis; S L Helfand; J Werkmeister; H F Pross; L A Boxer; S F Schlossman; A S Fauci
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.